AXSM (Axsome Therapeutics) Notes Receivable : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Notes Receivable?

Axsome Therapeutics's Notes Receivable for the quarter that ended in Sep. 2024 was $0.0 Mil.

Axsome Therapeutics Notes Receivable Historical Data

The historical data trend for Axsome Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Notes Receivable Chart

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Axsome Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Axsome Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Axsome Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

0HKF:UK 19X:Germany

Address

One World Trade Center, 22nd Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Executives

Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Roger Jeffs	director
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111